<DOC>
	<DOCNO>NCT01110824</DOCNO>
	<brief_summary>The investigator ' objective ass efficacy combine treatment enalapril carvedilol prevention leave ventricular systolic dysfunction patient hematological malignancy submit intensive chemotherapy potential cardiotoxicity . The hypothesis drug administer chemotherapy may prevent leave ventricular systolic dysfunction .</brief_summary>
	<brief_title>Prevention Left Ventricular Dysfunction During Chemotherapy</brief_title>
	<detailed_description>The prognosis patient hematological malignancy greatly improve last year use new chemotherapeutic drug regimens cost significant adverse event cardiac toxicity . Asymptomatic leave ventricular systolic dysfunction limit specific treatment patient long-term survival , since significant proportion relapse within 5 year front-line therapy require salvage treatment , include hematopoietic stem-cell transplantation instance . Angiotensin-converting enzyme inhibitor ( ACEIs ) show preventive effect chemotherapy-induced cardiotoxicity animal model , patient early cardiotoxicity . Carvedilol prevent free radical release , mitochondrial dysfunction , apoptosis , dilate cardiomyopathy animal treat anthracyclines , show promising result prevent chemotherapy-induced left ventricular dysfunction patient . As demonstrated post-infarction patient , combine treatment ACEI carvedilol could additive effect prevent LV dysfunction patient hematological malignancy high risk cardiac toxicity . Therefore , design OVERCOME ( preventiOn leave Ventricular dysfunction Enalapril caRvedilol patient submit intensive ChemOtherapy treatment Malignant hEmopathies ) study , prospective , randomized trial evaluate combine effect enalapril carvedilol prevention leave ventricular dysfunction patient malignant hemopathies undergo intensive chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Adult patient 1870 year old Sinus rhythm Normal LVEF ( &gt; =50 % ) Patients recently diagnose acute leukemia submit intensive chemotherapy Patients hemopathies submit autologous peripheral blood stem cell transplantation Signed informed consent Congestive heart failure LVEF &lt; 50 % Coronary artery disease , significant valvulopathy myocardiopathy Renal failure ( MDRD &lt; 30 ) Liver failure Ongoing expect need treat angiotensinconverting enzyme inhibitor ( ACEi ) , angiotensin II receptor blocker ( ARB ) betablockers Prior allergy ACEI ARB Systolic blood pressure &lt; 90 mmHg Asthma Auriculoventricular ( AV ) block sinus bradycardia ( HR &lt; 60 bpm ) Persistent atrial fibrillation Need treat Class I antiarrhythmic drug Pregnancy Inability unwillingness give unformed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Prevention</keyword>
	<keyword>ventricular dysfunction</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>precursor-cell lymphoblastic leukemia</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>ejection fraction</keyword>
	<keyword>Autologous hematopoietic stem cell transplantation</keyword>
</DOC>